Publications by authors named "Elin Reines"

Claim this Profile
V
Vortioxetine in treatment of depression with somatic comorbidities in routine practice: sub-group analysis of the RELIEVE study.
David S Baldwin, Amar Mehta, Daniel Oudin Åström, Elin H Reines, GregoryW Mattingly

J Affect Disord· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Tolerability of Vortioxetine Oral Drops Versus Oral Tablets in Major Depressive Disorder: An Analysis of a Real-World Cohort Study in Switzerland.
Barbara Hochstrasser, Gregor Hasler, Axel Baumann, Rohini Bose, Elin Reines

CNS Drugs· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time to efficacious steady state plasma concentrations with slow titration of Vortioxetine drops versus oral tablets: a Pharmacokinetic model.
Andrea Fagiolini, Elin H Reines, Anja Farovik, Johan Areberg

Ann Gen Psychiatry· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Functional improvement as a treatment goal in major depressive disorder: a narrative review of the evidence for vortioxetine.
Pratap Chokka, Lene Hammer-Helmich, Simon Nitschky Schmidt, Martine Hubert, Elin H Reines

Curr Med Res Opin· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vortioxetine in the routine management of major depressive disorder: an analysis of European automated healthcare databases.
Frank Andersohn, Michael Cronquist Christensen, Lambert Creuwels, Ignacio Aznar-Lou, Maria Rubio-Valera, Elin H Reines

Curr Med Res Opin· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vortioxetine in the Treatment of Major Depressive Disorder Among Working Patients in Routine Clinical Practice: An Analysis of a Post-Marketing Surveillance Study in South Korea.
Seok Woo Moon, Jee Wook Kim, Do Hoon Kim, Michael Adair, Daniel Oudin Åström, Elin Heldbo Reines

Neuropsychiatr Dis Treat· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Minimal clinically important change in the MADRS anhedonia factor score: A pooled analysis of open-label studies with vortioxetine in patients with major depressive disorder.
Roger S McIntyre, Oscar Necking, Simon Nitschky Schmidt, Elin Reines

J Affect Disord· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Goal setting and goal attainment in patients with major depressive disorder: a narrative review on shared decision making in clinical practice.
David S Baldwin, Michael Adair, Arun Micheelsen, Daniel Oudin Åstrøm, Elin H Reines

Curr Med Res Opin· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and efficacy, including anhedonia, of vortioxetine for major depressive disorder: findings from two open-label studies.
Gregory W Mattingly, Oscar Necking, Simon Nitschky Schmidt, Elin Reines, Hongye Ren

Curr Med Res Opin· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and effectiveness of vortioxetine for major depressive disorder: Real-world evidence from a population-based study in South Korea.
Seok Woo Moon, Jee Wook Kim, Do Hoon Kim, Kyu Young Lee, Elin Heldbo Reines

Front Psychiatry· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness.
David S Baldwin, Oscar Necking, Simon Nitschky Schmidt, Hongye Ren, Elin H Reines

J Affect Disord· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Persistence of Nalmefene Treatment for Alcohol Dependence. Results from Two Post-authorisation Safety Studies.
Jonathan Chick, Frank Andersohn, Sylvie Guillo, Kathrin Borchert, Massoud Toussi, Elin Heldbo Reines

Alcohol Alcohol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Response Trajectories in Major Depressive Disorder.
Klaus G Larsen, Sidney H Kennedy, Elin Heldbo Reines, Michael E Thase

Psychopharmacol Bull· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management of Depression in Adolescents in Japan.
Takuya Saito, Elin H Reines, Ioana Florea, Mads K Dalsgaard

J Child Adolesc Psychopharmacol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of escitalopram in the treatment of social anxiety disorder: A meta-analysis versus placebo.
David S Baldwin, Satoshi Asakura, Tsukasa Koyama, Taiji Hayano, Atsushi Hagino, Elin Reines

Eur Neuropsychopharmacol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies.
David S Baldwin, Lambros Chrones, Ioana Florea, Rebecca Nielsen, George G Nomikos, Elin Reines

J Psychopharmacol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
Connie Sanchez, Elin H Reines, Stuart A Montgomery

Int Clin Psychopharmacol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cardiovascular safety profile of escitalopram.
Michael E Thase, Klaus G Larsen, Elin Reines, Sidney H Kennedy

Eur Neuropsychopharmacol· November 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Satisfaction with medication is correlated with outcome but not persistence in patients treated with placebo, escitalopram, or serotonin-norepinephrine reuptake inhibitors: a post hoc analysis.
Koen Demyttenaere, Elin Heldbo Reines, Sara Larsson Lönn, Malcolm Lader

Prim Care Companion CNS Disord· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.
Koen Demyttenaere, Henning Friis Andersen, Elin Heldbo Reines

Int Clin Psychopharmacol· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Escitalopram therapy for major depression and anxiety disorders.
David S Baldwin, Elin Heldbo Reines, Christina Guiton, Emmanuelle Weiller

Ann Pharmacother· October 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
Lucien Colonna, Henning Friis Andersen, Elin Heldbo Reines

Curr Med Res Opin· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Escitalopram versus citalopram: the surprising role of the R-enantiomer.
Connie Sánchez, Klaus P Bøgesø, Bjarke Ebert, Elin Heldbo Reines, Claus Braestrup

Psychopharmacology (Berl)· July 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.
Ulla M Lepola, Henrik Loft, Elin Heldbo Reines

Int Clin Psychopharmacol· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis